Byetta

(Exenatide)

ApprovedPeptide

Exenatide is used to help control blood sugar levels in people with type 2 diabetes. It works by helping the pancreas release the right amount of insulin when blood sugar is high.[2] Byetta is currently approved and in use across 15 indications[4].[1]

Byetta is one of 349 small molecule programs targeting Acute Pancreatitis. It is currently in Approved.

Indications

203

Total Trials

Active Trials

348

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Acute PancreatitisActive, not recruiting

Gestational DiabetesWithdrawn

HepatitisActive, not recruiting

Prader-Willi SyndromeActive, not recruiting

Diabetic NephropathyCompleted

Wolfram SyndromeActive, not recruiting

Brain InjuryCompleted

Diastolic Heart FailureTerminated

Congestive Heart FailureCompleted

HyperglycemiaCompleted

Acute PancreatitisPreclinical

Active, not recruiting

Gestational DiabetesApproved

Withdrawn

HepatitisApproved

Active, not recruiting

Prader-Willi SyndromePreclinical

Active, not recruiting

Diabetic NephropathyApproved

Completed

Wolfram SyndromePreclinical

Active, not recruiting

Brain InjuryApproved

Completed

Diastolic Heart FailureApproved

Terminated

Congestive Heart FailureApproved

Completed

HyperglycemiaApproved

Completed

Showing 10 of 15 indications

Competition

Competitive Landscape

307 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Byetta

AstraZeneca

Approved

1 2

Medrol

Pfizer

Preclinical

1 3

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 5

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Preclinical

1 6

Active Comparator

Moderna

Preclinical

1 7

Secretin-Ferring

Ferring

Preclinical

1 8

Sulfonylureas

Eli Lilly

Preclinical

1 9

PEG-Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

1 10

Cyclophosphamid

EEssen Biotech

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

GLP-1

NCT05356104

Clinical

Trials by Indication[1]

Type 2 Diabetes55 trials

Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00658021·122 enrolled

Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01664624·40 enrolled

Exenatide Versus Glimepiride in Patients With Type 2 Diabetes

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00359762·1,029 enrolled

Show 52 more trials

Study of Comparison the Treatment Effect Between Gastric Bypass and Exenatide in Type 2 Diabetes

Unknown status·WWu Qinan·Phase 4·NCT01435980·60 enrolled

Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00082407·505 enrolled

Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea

Completed· AstraZeneca logo

AstraZeneca··NCT02090673·1,711 enrolled

A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.

Completed· Gilead logo

Gilead·Phase 1·NCT01843127·24 enrolled

Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT01885208·813 enrolled

Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s)

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00577824·181 enrolled

Exenatide and Basal Insulins Use in the Real Setting: an Observational Study in Patients With Type 2 Diabetes

Completed· AstraZeneca logo

AstraZeneca··NCT01060059·888 enrolled

A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00960661·1,036 enrolled

Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00111540·456 enrolled

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT01676116·438 enrolled

CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy

Completed· AstraZeneca logo

AstraZeneca··NCT00635492·2,515 enrolled

Effects of Exenatide on Glycemic Control and Weight in Continuous Subcutaneous Insulin Infusion (CSII) Type 2 Treated Patients With Type 2 Diabetes

Unknown status·UUniversity Hospital, Caen·Phase 2/3·NCT01140893·110 enrolled

Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT00313001·373 enrolled

Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes

Completed·EEmory University·Phase 4·NCT02455076·150 enrolled

An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 Diabetes

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00516048·58 enrolled

Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes

Completed·FFudan University·Phase 4·NCT02303730·76 enrolled

Efficacy and Mechanism of Exenatide on Improving Heart Function in Type 2 Diabetes With Heart Failure Patients

Unknown status·—·N/A·NCT02344641·234 enrolled

Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00729326·83 enrolled

GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

Completed· Sanofi logo

Sanofi·Phase 3·NCT00707031·639 enrolled

A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 Diabetes

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00516074·54 enrolled

Impact of Exenatide on Cardiovascular Exercise Performance in Type 2 Diabetes

Completed·UUniversity of Colorado, Denver·N/A·NCT01364584·23 enrolled

Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT00518882·467 enrolled

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

Completed· Sanofi logo

Sanofi·Phase 3·NCT02787551·514 enrolled

A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00637273·514 enrolled

Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00434954·494 enrolled

Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00676338·820 enrolled

Exeantide in Type 2 Diabetes on Insulin

Completed·UUniversity at Buffalo·Phase 2·NCT01154933·24 enrolled

Subanalyses of Elderly Type 2 Diabetes Patients or Type 2 Diabetes Patients With Renal Impairment

Completed· AstraZeneca logo

AstraZeneca··NCT02917057·6,024 enrolled

Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT01003184·222 enrolled

Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00641056·467 enrolled

Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00082381·551 enrolled

A Study to Examine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients With Type 2 Diabetes

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT00612794·30 enrolled

Comparison of Type 2 Diabetes Pharmacotherapy Regimens

Completed·KKaiser Permanente··NCT05073692·241,981 enrolled

A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 Diabetes

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00382239·153 enrolled

Exenatide Once Weekly, Cardiovascular Risk and Type-2 Diabetes

Completed·UUniversity of Palermo·Phase 4·NCT02380521·60 enrolled

Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT01029886·912 enrolled

Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT01554618·84 enrolled

Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT01652716·377 enrolled

A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes

Completed·OOPKO Health, Inc.·Phase 2·NCT02119819·420 enrolled

Effect of Exenatide on Glucose Homeostasis Determinants in Type 2 Diabetes

Completed·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·Phase 4·NCT00948168·34 enrolled

Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00324363·466 enrolled

The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes

Completed·JJoslin Diabetes Center·Phase 4·NCT00353834·72 enrolled

Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes

Completed·XXijing Hospital·Phase 4·NCT02449603·150 enrolled

Comparison of Exenatide Taken Before Lunch and Dinner With Before Breakfast and Dinner in Patients With Type 2 Diabetes

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00359879·377 enrolled

A Study of the Effect of Glucagon-like Peptide 1(GLP-1) Receptor Agonist in Combination With Metformin Therapy on Diabetes Remission in Subjects With Newly Diagnosed Type 2 Diabetes Who Are Overweight or Obese

Unknown status·TThe First Hospital of Jilin University·Phase 4·NCT03018665·200 enrolled

Impact of Exenatide on Sleep in Type 2 Diabetes

Completed·UUniversity of Chicago·N/A·NCT01136798·18 enrolled

A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00360334·235 enrolled

Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00603239·165 enrolled

Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00099320·182 enrolled

Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00241423·30 enrolled

Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00097500·69 enrolled

Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin

Terminated· AstraZeneca logo

AstraZeneca·Phase 2·NCT00701935·80 enrolled

Type 2 Diabetes Mellitus20 trials

Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus.

Completed·MMedical University of Vienna·Phase 4·NCT03007329·34 enrolled

A Study in Participants With Type 2 Diabetes Mellitus

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT01064687·978 enrolled

A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.

Completed· Roche logo

Roche·Phase 3·NCT00717457·1,189 enrolled

Show 17 more trials

Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00308139·303 enrolled

Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00085969·99 enrolled

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT01144338·14,752 enrolled

Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT01652729·365 enrolled

A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)

Terminated· Eli Lilly logo

Eli Lilly·Phase 4·NCT02072096·192 enrolled

Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00935532·427 enrolled

Study of Exenatide Once-Weekly Suspension in Chinese Patients With Type 2 Diabetes Mellitus

Withdrawn· AstraZeneca logo

AstraZeneca·Phase 1·NCT04001231

Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus

Completed·IIntarcia Therapeutics·Phase 2·NCT00943917·155 enrolled

Clinical Trial for PB-119 in Subjects With Type 2 Diabetes Mellitus

Completed·PPegBio Co., Ltd.·Phase 1·NCT03059719·36 enrolled

A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00877890·254 enrolled

An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects

Terminated· GSK logo

GSK·Phase 4·NCT02793154·4 enrolled

Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00765817·261 enrolled

Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00753896·134 enrolled

An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00135330·137 enrolled

An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT01876849·275 enrolled

In-patient Study in Patients With Type 2 Diabetes Mellitus

Completed· GSK logo

GSK·Phase 1·NCT00259896·30 enrolled

A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes Mellitus

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00477581·102 enrolled

Obesity5 trials

Double-blinded, 6 Months Study With Bydureon® or Placebo in Adolescents With Obesity to Explore Changes in BMI

Completed·UUppsala University·Phase 2·NCT02794402·44 enrolled

Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue

Completed·—·Phase 3·NCT01794429·45 enrolled

Exenatide in Extreme Pediatric Obesity

Completed·UUniversity of Minnesota·Phase 2·NCT01237197·26 enrolled

Show 2 more trials

The Effect of GLP-1 Receptor Activation on Central Reward and Satiety in Obesity and Diabetes

Completed·AAmsterdam UMC, location VUmc·N/A·NCT01281228·48 enrolled

GLP-1 Agonism Stimulates Browning of Subcutaneous White Adipose Tissue in Obesity Men

Completed·XXiang Guang-da·Phase 4·NCT02170324·20 enrolled

GLP-15 trials

Haemodynamic Effects of GLP-1 and Glucagon in Healthy Male Volunteers

Completed·—·N/A·NCT03835013·26 enrolled

GLP-1 Agonism for Blocking Cocaine Euphoria and Self-Administration

Completed·YYale University·Phase 1·NCT02302976·13 enrolled

Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist

Terminated·UUniversity of Alabama at Birmingham·Phase 4·NCT01381926·14 enrolled

Show 2 more trials

GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)

Recruiting·—·Phase 2·NCT05356104·110 enrolled

FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)

Completed·UUniversity of Washington·Phase 4·NCT01524705·102 enrolled

Dapagliflozin4 trials

Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 4·NCT03331289·107 enrolled

The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients

Terminated·UUniversitätsklinikum Hamburg-Eppendorf·Phase 3·NCT03419624·13 enrolled

Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.

Completed·CConsano Clinical Research, LLC·Phase 4·NCT03970044·67 enrolled

Show 1 more trial

Exploratory Study to Investigate the Effect of Dapagliflozin and Exenatide Combined on Body Weight

Completed·UUppsala University·Phase 2·NCT02313220·50 enrolled

78 more indications

Type 1 Diabetes4 trials

Exenatide and Impaired Hypoglycaemic Awareness in Type 1 Diabetes

Completed·RRadboud University Medical Center·Phase 2/3·NCT02735031·10 enrolled

Study of the Acute Metabolic Effect of Exenatide in Type 1 Diabetes

Completed·YYale University·Phase 1·NCT01855490·17 enrolled

Role of Exenatide in Type 1 Diabetes

Completed·MMontefiore Medical Center·Phase 2·NCT00456300·11 enrolled

Show 1 more trial

New Onset Type 1 Diabetes: Role of Exenatide

Completed·—·Phase 4·NCT01269034·13 enrolled

Parkinson's Disease4 trials

Trial of Exenatide for Parkinson's Disease

Completed·UUniversity College, London·Phase 2·NCT01971242·60 enrolled

Exenatide Treatment in Parkinson's Disease

Unknown status·CCenter for Neurology, Stockholm·Phase 2·NCT04305002·60 enrolled

Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease

Unknown status·UUniversity College, London·Phase 3·NCT04232969·194 enrolled

Show 1 more trial

Exendin-4 as a Treatment for Parkinson's Disease - Pilot Study

Unknown status·UUniversity College, London·Phase 2·NCT01174810·40 enrolled

Type 2 Diabetic Patients3 trials

Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic Patients

Completed·SSun Yat-sen University·N/A·NCT01147627·416 enrolled

Additional GLP-1 Analogue on CSII Treatment for Poorly Controlled Type 2 Diabetic Patients

Completed·—·N/A·NCT01473147·51 enrolled

The Effects of Short-Term Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients

Unknown status·TTaipei Veterans General Hospital, Taiwan·Phase 4·NCT01270191·160 enrolled

Hypothalamic Obesity3 trials

Effects of Exenatide on Hypothalamic Obesity

Completed·—·Phase 1/2·NCT01061775·19 enrolled

Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity

Completed·SSeattle Children's Hospital·Phase 3·NCT02664441·42 enrolled

Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy

Completed·UUniversity Hospital, Bordeaux·Phase 3·NCT02860923·42 enrolled

Weight loss3 trials

Weight Loss With Exenatide Treatment

Completed·JJody Dushay·Phase 4·NCT01590433·249 enrolled

Effect on Weight Loss of Exenatide Versus Placebo

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00375492·196 enrolled

GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children

Completed·UUniversity of Minnesota·Phase 2·NCT00886626·12 enrolled

Overweight3 trials

Research of Exenatide for Overweight/Obese PCOS Patients With IGR

Completed·RRenJi Hospital·Phase 4·NCT03352869·183 enrolled

Metformin vs Metformin Combined With GLP-1RA (Glucagon-like Peptide 1 Receptor Agonist) on Overweight/Obese PCOS Patients

Unknown status·PPeking Union Medical College Hospital·Phase 4·NCT04029272·80 enrolled

Effects of GLP-1 Analogue Combined With Metformin and Metformin on Gonadal and Metabolic Profiles in Chinese Overweight/Obese PCOS Patients With Hyperandrogenemia.

Completed·BBing He·Phase 4·NCT04969627·60 enrolled

Function3 trials

Glucagon-like Peptide 1 Agonist Exenatide for Improved Glucose Control and Cardiac Function in Patients With Aortocoronary Bypass

Completed·—·Phase 3·NCT01373216·38 enrolled

Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass

Completed·UUniversity of Pennsylvania·N/A·NCT00775684·47 enrolled

Effect on Beta Cell Function and Glycaemic Control After Insulin and Exenatide Sequential Therapy

Unknown status·Xxiaolong zhao·Phase 4·NCT02129985·100 enrolled

PreDiabetes2 trials

The Vascular Effects of Exenatide Versus Metformin in Patients With Pre-Diabetes

Completed·SSt. Paul Heart Clinic·Phase 4·NCT00546728·50 enrolled

Effects of Antidiabetic Medications on the Postprandial State in Prediabetes

Completed·TThe University of Texas Health Science Center, Houston·Phase 4·NCT02104739·21 enrolled

Hyperinsulinemic Hypoglycemia2 trials

Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia

Completed·UUniversity of Minnesota·Phase 1·NCT02685852·11 enrolled

Exenatide-test for Diagnosing Endogenous Hyperinsulinemic Hypoglycemia

Completed·UUniversity Hospital, Basel, Switzerland·N/A·NCT04909333·29 enrolled

Diabetes Mellitus2 trials

Effects of Exenatide on Obesity and/or Diabetes Mellitus Due to Hypothalamic Damage

Unknown status·HHuashan Hospital·N/A·NCT01783717·10 enrolled

Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT02229383·464 enrolled

Weight Gain2 trials

How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics

Completed·OOregon Health and Science University·Phase 4·NCT00667732·41 enrolled

Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults

Completed·UUniversity of Cincinnati·Phase 4·NCT00845507·54 enrolled

Obese Women2 trials

Effects of the GLP-1 Exenatide on Satiety in Lean and Obese Women

Completed·UUniversity of California, Los Angeles·Phase 1·NCT01501084·34 enrolled

EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)

Completed·WWoman's·Phase 3·NCT02635386·119 enrolled

Hyperglycemia2 trials

Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia

Completed·—·Phase 4·NCT01269047·37 enrolled

Exenatide for Stress Hyperglycemia

Completed·—·Phase 2/3·NCT01969149·110 enrolled

Gastric Emptying2 trials

Effect of Exenatide in Obese Patients With Accelerated Gastric Emptying

Completed·MMayo Clinic·Phase 4·NCT02160990·20 enrolled

The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying Rate

Unknown status·HHvidovre University Hospital·Phase 2/3·NCT02584582·10 enrolled

Prader-Willi syndrome2 trials

Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome

Completed·GGarvan Institute of Medical Research·N/A·NCT00551343·20 enrolled

Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome

Completed·—·N/A·NCT01444898·10 enrolled

Gestational Diabetes2 trials

Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes

Recruiting·—·Phase 4·NCT05482789·13 enrolled

Pilot Study of Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes

Withdrawn·GGeorgetown University·Phase 4·NCT00572689

Alcohol Dependence2 trials

Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?

Completed·AAnders Fink-Jensen, MD, DMSci·Phase 2·NCT03232112·152 enrolled

Gut Hormones in Obesity, Nicotine and Alcohol Dependence

Unknown status·IImperial College London·Phase 1·NCT02690987·95 enrolled

Pilot Study2 trials

Pilot Study of Bydureon to Treat Diabetes in HIV-infected Adults

Terminated·VVanderbilt University·Phase 4·NCT01791465·6 enrolled

Role of Exenatide in NASH-a Pilot Study

Completed·IIndiana University·Phase 2/3·NCT00650546·8 enrolled

Safety and Efficacy2 trials

A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly Suspension

Completed· AstraZeneca logo

AstraZeneca·Phase 1/2·NCT00894322·65 enrolled

Safety and Efficacy of Exenatide as Monotherapy

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00381342·233 enrolled

Treatment2 trials

Diabetes Islet Preservation Immune Treatment

Withdrawn·CCamillo Ricordi and Jay Skyler·Phase 1/2·NCT02586831

Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes

Completed·—·Phase 4·NCT01432405·24 enrolled

Obese Patients2 trials

Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients

Unknown status·XXiangya Hospital of Central South University·Phase 3·NCT03671733·150 enrolled

A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00500370·163 enrolled

Diabetes, Type 21 trial

DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2

Completed·AAmsterdam UMC, location VUmc·Phase 4·NCT03361098·65 enrolled

Body Weight1 trial

Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 4·NCT00845182·43 enrolled

Hepatitis1 trial

Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH)

Completed·RRuhr University of Bochum·Phase 4·NCT01208649·13 enrolled

Cardiac Surgery1 trial

Impact of Perioperative Exenatide Infusion on Quality of Life in Cardiac Surgery Patients

Completed·—·Phase 2/3·NCT02432976·64 enrolled

Adverse Reaction1 trial

Safety Evaluation of Adverse Reactions in Diabetes

Completed·—·Phase 4·NCT02092597·42 enrolled

Sepsis1 trial

Pharmacology of Exenatide in Pediatric Sepsis

Withdrawn·SSeattle Children's Hospital·Phase 1/2·NCT01573806

Myocardial Infarction1 trial

COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial

Completed·HHospital Universitari Vall d'Hebron Research Institute·Phase 3·NCT02404376·378 enrolled

Heavy Drinker1 trial

The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers

Terminated·—·Phase 1·NCT03645408·8 enrolled

Gastric1 trial

The Effects of Exenatide After Gastric Restriction

Unknown status·AAdvanced Specialty Care·Phase 2/3·NCT00872378·28 enrolled

Motor Function1 trial

Effects of Exenatide on Motor Function and the Brain

Completed·UUniversity of Florida·Phase 1·NCT03456687·5 enrolled

Craniopharyngioma1 trial

Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor

Completed·VVanderbilt University Medical Center·Phase 2·NCT01484873·10 enrolled

Diabetic Neuropathy1 trial

Evaluation of Exenatide in Patients With Diabetic Neuropathy

Completed·UUniversity of Michigan·N/A·NCT00855439·46 enrolled

Hyperlipidemia1 trial

Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation

Completed·—·Phase 4·NCT00974272·39 enrolled

Acute Pancreatitis1 trial

A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents

Completed· AstraZeneca logo

AstraZeneca··NCT01077323·363,766 enrolled

Type 1 Diabetic1 trial

Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetic Cases

Completed·FFilip Krag Knop·Phase 2·NCT03017352·108 enrolled

Wolfram syndrome1 trial

GLP Analogs for Diabetes in Wolfram Syndrome Patients

Withdrawn·HHadassah Medical Organization·N/A·NCT01302327

Type 1 Diabetes Mellitus1 trial

Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus

Completed·—·Phase 4·NCT01235819·20 enrolled

Non-Alcoholic Fatty Liver Disease1 trial

Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease

Completed·UUniversity of Florida·Phase 4·NCT01006889·24 enrolled

Concentration1 trial

A Safety Study to Assess the Effects of Therapeutic and Supratherapeutic Exenatide Concentrations on QT Interval in Healthy Subjects

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01297062·94 enrolled

Conditioning1 trial

Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI

Completed·RRigshospitalet, Denmark·Phase 4·NCT00835848·100 enrolled

Adult1 trial

The Effects of Exenatide on Post-Meal Sugar Peaks and Vascular Health in Obese/Pre-Diabetic Young Adults

Withdrawn·YYale University·Phase 4·NCT00845559

Sleep1 trial

Impact of Exenatide on Sleep Duration

Completed·UUniversity of Chicago··NCT01416649·8 enrolled

Intensive Care Unit1 trial

Intravenous Exenatide in Coronary Intensive Care Unit (ICU) Patients

Completed·SSaint Luke's Health System·Phase 4·NCT00736229·40 enrolled

Completed·IIntarcia Therapeutics·Phase 1·NCT02650479·82 enrolled

Women1 trial

The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women

Completed·—·Phase 4·NCT00456885·41 enrolled

Fatty Liver Disease1 trial

Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease

Terminated·UUniversity of California, Davis·Phase 2·NCT00529204·1 enrolled

Humans1 trial

Exenatide (Byetta ®) Regulation of Intestinal and Hepatic Lipoprotein Particle Production in Humans

Completed·UUniversity Health Network, Toronto·N/A·NCT01056549·15 enrolled

Insulin Sensitivity1 trial

Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 4·NCT02981069·90 enrolled

Blood Pressure1 trial

Study Looking at Cardiovascular Effects of Exenatide, Its Blood Pressure Lowering Effect and Its Mechanisms

Completed·UUniversity of Nottingham·N/A·NCT01046721·8 enrolled

Effectiveness1 trial

Comparison of the Effectiveness and Tolerability of Exenatide Once-weekly Compared to Basal Insulins

Completed· AstraZeneca logo

AstraZeneca··NCT02974244·7,000 enrolled

Efficacy1 trial

A Study to Examine the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly Suspension

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT01104701·121 enrolled

Outcome1 trial

Clinical Outcomes of Exenatide Versus Basal Insulin

Completed· AstraZeneca logo

AstraZeneca··NCT02987348·18,000 enrolled

Diabetes1 trial

A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes

Completed·YYale University·Phase 2·NCT01928329·79 enrolled

Cocaine Use Disorder1 trial

Exenatide for Treating Cocaine Use Disorder

Completed·TThe University of Texas Health Science Center, Houston·Phase 1/2·NCT04941521·3 enrolled

Cortisol1 trial

Effect of Exenatide on Cortisol Secretion

Completed·UUniversity of Tartu·Phase 4·NCT03160261·10 enrolled

Stroke1 trial

Trial of EXenatide in Acute Ischaemic Stroke

Unknown status·NNeuroscience Trials Australia·Phase 2·NCT03287076·350 enrolled

Sts1 trial

Pharmacogenomics of GLP1 Receptor Agonists

Terminated·UUniversity of Maryland, Baltimore·Phase 1·NCT05762744·63 enrolled

Acute Myocardial Infarction1 trial

Effect of Additional Treatment With EXenatide in Patients With an Acute Myocardial Infarction (the EXAMI Trial)

Unknown status·AAmsterdam UMC, location VUmc·Phase 3·NCT01254123·40 enrolled

Children1 trial

Brain Activation and Satiety in Children 2

Active, not recruiting·SSeattle Children's Hospital·Phase 3·NCT04520490·63 enrolled

Interaction1 trial

Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection

Completed· Theracos logo

Theracos·Phase 1·NCT03167411·20 enrolled

Short Bowel Syndrome1 trial

Exenatide on GI Motor Function and Permeability in Short Bowel Syndrome

Withdrawn·MMayo Clinic·Phase 4·NCT01818648

Diastolic Heart Failure1 trial

Evaluating the Use of Exenatide in People With Type 2 Diabetes and Diastolic Heart Failure

Terminated·—·Phase 4·NCT00799435·2 enrolled

Myocardial Protection1 trial

Exenatide for Myocardial Protection During Reperfusion Study

Unknown status·UUniversity Health Network, Toronto·Phase 2·NCT01938235·198 enrolled

Smoking Cessation1 trial

Exenatide Once Weekly for Smoking Cessation

Completed·TThe University of Texas Health Science Center, Houston·Phase 1/2·NCT02975297·84 enrolled

Inflammation1 trial

Effect of Exenatide on Liver and Heart Fat and Inflammation

Completed·—·Phase 4·NCT01951651·24 enrolled

Congestive Heart Failure1 trial

Effects of Exenatide in Type 2 Diabetic Patients With Congestive Heart Failure

Completed·AAmsterdam UMC, location VUmc·Phase 4·NCT00766857·27 enrolled

Brain Injury1 trial

Intravenous Exenatide in Patients With Acute Brain Injury

Completed·UUniversity of North Carolina, Chapel Hill·Phase 4·NCT02058940·8 enrolled

Pregnancy1 trial

Research of Intensive Metabolic Intervention Before Pregnancy in PCOS

Unknown status·RRenJi Hospital·Phase 4·NCT03383068·160 enrolled

Cognitive Decline1 trial

Long-acting Exenatide and Cognitive Decline in Dysglycemic Patients

Unknown status·AAzienda Ospedaliero-Universitaria di Parma·Phase 3·NCT02847403·40 enrolled

AIN1 trial

Exenatide For Reducing the Reinforcing Effects of Cocaine

Withdrawn·—·Phase 1·NCT06252623

Schizophrenia1 trial

Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia

Completed·UUniversity of Massachusetts, Worcester·Phase 4·NCT02417142·70 enrolled

Infusion1 trial

Feasibility Study of Exenatide by Continuous Subcutaneous Infusion

Completed· GSK logo

GSK·Phase 1·NCT01857895·10 enrolled

Oral1 trial

Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00099333·49 enrolled

CAR1 trial

Electrophysiological Effects of a Single 10 μg Dose of Exenatide on the 12-Lead Electrocardiogram QT Interval in Healthy Subjects

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT00672399·70 enrolled

Unspecified4 trials

Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin Glargine

Completed·HHealthPartners Institute·N/A·NCT01089569·60 enrolled

Bioenergetic Alterations After Exenatide Administration

Completed·UUniversity of Wisconsin, Madison·Phase 4·NCT00623545·28 enrolled

A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00917267·691 enrolled

Show 1 more trial

SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies

Completed·AAmsterdam UMC, location VUmc·Phase 4·NCT01744236·70 enrolled

Regulatory

FDA Approval Timeline[5]

Apr 28, 2005

BYETTA

NDA NDA021773

Oct 12, 2006

BYETTA

NDA NDA021773

Nov 1, 2006

BYETTA

NDA NDA021773

Dec 22, 2006

BYETTA

NDA NDA021773

Dec 22, 2006

BYETTA

NDA NDA021773

Feb 10, 2007

BYETTA

NDA NDA021773

Jan 11, 2008

BYETTA

NDA NDA021773

Jun 17, 2008

BYETTA

NDA NDA021773

Oct 30, 2009

BYETTA

NDA NDA021773

Oct 30, 2009

BYETTA

NDA NDA021773

Oct 30, 2009

BYETTA

NDA NDA021773

Oct 30, 2009

BYETTA

NDA NDA021773

Oct 30, 2009

BYETTA

NDA NDA021773

Oct 30, 2009

BYETTA

NDA NDA021773

Aug 13, 2010

BYETTA

NDA NDA021773

Nov 12, 2010

BYETTA

NDA NDA021773

Aug 5, 2011

BYETTA

NDA NDA021773

Oct 19, 2011

BYETTA

NDA NDA021773

Oct 19, 2011

BYETTA

NDA NDA021773

Jan 30, 2014

BYETTA

NDA NDA021773

Apr 23, 2014

BYETTA

NDA NDA021773

Jun 4, 2014

BYETTA

NDA NDA021773

Jun 4, 2014

BYETTA

NDA NDA021773

Aug 12, 2014

BYETTA

NDA NDA021773

Nov 24, 2014

BYETTA

NDA NDA021773

Feb 25, 2015

BYETTA

NDA NDA021773

Dec 20, 2018

BYETTA

NDA NDA021773

Feb 28, 2020

BYETTA

NDA NDA021773

Jun 17, 2021

BYETTA

NDA NDA021773

Nov 4, 2021

BYETTA

NDA NDA021773

Jun 10, 2022

BYETTA

NDA NDA021773

Jun 10, 2022

BYETTA

NDA NDA021773

Dec 21, 2022

BYETTA

NDA NDA021773

Nov 1, 2024

BYETTA

NDA NDA021773

May 28, 2025

BYETTA

NDA NDA021773

Sep 2, 2025

BYETTA

NDA NDA021773

Sources

References

[1]
ClinicalTrials.gov — 203 trial records for Exenatide. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Byetta drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Exenatide compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Exenatide. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA021773). U.S. Food & Drug Administration.
[6]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Glucagon-Like Peptide 1 Receptor Agonist[3]
Modality: Peptide[3]
Highest Phase: Approved[1]
Company: AstraZeneca

Byetta

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Type 2 Diabetes55 trials

Type 2 Diabetes Mellitus20 trials

Obesity5 trials

GLP-15 trials

Dapagliflozin4 trials

Type 1 Diabetes4 trials

Parkinson's Disease4 trials

Type 2 Diabetic Patients3 trials

Hypothalamic Obesity3 trials

Weight loss3 trials

Overweight3 trials

Function3 trials

PreDiabetes2 trials

Hyperinsulinemic Hypoglycemia2 trials

Diabetes Mellitus2 trials

Weight Gain2 trials

Obese Women2 trials

Hyperglycemia2 trials

Gastric Emptying2 trials

Prader-Willi syndrome2 trials

Gestational Diabetes2 trials

Alcohol Dependence2 trials

Pilot Study2 trials

Safety and Efficacy2 trials

Treatment2 trials

Obese Patients2 trials

Diabetes, Type 21 trial

Body Weight1 trial

Hepatitis1 trial

Cardiac Surgery1 trial

Adverse Reaction1 trial

Sepsis1 trial

Myocardial Infarction1 trial

Heavy Drinker1 trial

Gastric1 trial

Motor Function1 trial

Craniopharyngioma1 trial

Diabetic Neuropathy1 trial

Hyperlipidemia1 trial

Acute Pancreatitis1 trial

Type 1 Diabetic1 trial

Wolfram syndrome1 trial

Type 1 Diabetes Mellitus1 trial

Non-Alcoholic Fatty Liver Disease1 trial

Concentration1 trial

Conditioning1 trial

Adult1 trial

Sleep1 trial

Intensive Care Unit1 trial

Metabolism1 trial

MPA1 trial

Cardiac Repolarization1 trial

Women1 trial

Fatty Liver Disease1 trial

Humans1 trial

Insulin Sensitivity1 trial

Blood Pressure1 trial

Effectiveness1 trial

Efficacy1 trial

Outcome1 trial

Diabetes1 trial

Cocaine Use Disorder1 trial

Cortisol1 trial

Stroke1 trial

Sts1 trial

Acute Myocardial Infarction1 trial

Children1 trial

Interaction1 trial

Short Bowel Syndrome1 trial

Diastolic Heart Failure1 trial

Myocardial Protection1 trial

Smoking Cessation1 trial

Inflammation1 trial

Congestive Heart Failure1 trial